Small-molecule targeting of translation initiation for cancer therapy

Bertal H. Aktas; Yuan Qiao; Esra Ozdelen; Roland Schubert; Sema Sevinc; Fred Harbinski; Luciano Grubissich; Samuel Singer; Jose A. Halperin

doi:10.18632/oncotarget.1186

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Small-molecule targeting of translation initiation for cancer therapy

Bertal H. Aktas _, Yuan Qiao, Esra Ozdelen, Roland Schubert, Sema Sevinc, Fred Harbinski, Luciano Grubissich, Samuel Singer and Jose A. Halperin

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2013; 4:1606-1617. https://doi.org/10.18632/oncotarget.1186

Metrics: PDF 2401 views | HTML 2955 views | ?

Abstract

Bertal H. Aktas1,2, Yuan Qiao2, Esra Ozdelen2, Roland Schubert2, Sema Sevinc2, Fred Harbinski2, Luciano Grubissich2, Samuel Singer3, Jose A. Halperin1,2

1 Department of Medicine, Brigham and Women’s Hospital, Boston;

2 Laboratory for Translational Research, Harvard Medical School, Boston;

3 Department of Surgery, Brigham and Women’s Hospital, Boston.

Correspondence:

Jose A. Halperin, email:

Keywords: CANCER, TERNARY COMPLEX, TRANSLATION, eIF2, UTR

Received: July 15, 2013 Accepted: August 12, 2013 Published: August 14, 2013

Abstract

Translation initiation plays a critical role in the regulation of cell growth and tumorigenesis. We report here that inhibiting translation initiation through induction of eIF2α phosphorylation by small-molecular-weight compounds restricts the availability of the eIF2.GTP.Met-tRNAi ternary complex and abrogates the proliferation of cancer cells in vitro and tumor growth in vivo. Restricting the availability of the ternary complex preferentially down-regulates the expression of growth-promoting proteins and up-regulates the expression of ER stress response genes in cancer cells as well as in tumors excised from either animal models of human cancer or cancer patients. These findings provide the first direct evidence for translational control of gene-specific expression by small molecules in vivo and indicate that translation initiation factors are bona fide targets for development of mechanism-specific anti-cancer agents.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1186

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Small-molecule targeting of translation initiation for cancer therapy

Abstract